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Abstract. Clinical definitions of Parkinson’s disease (PD) are over 200 years old, while neuropathological definitions—which
are still the basis of how we define the disease now—are over 100 years old. We argue that for both clinical care and thera-
peutic development, these definitions need updating for the molecular age in which we live. We highlight specific instances
in which genetic or biochemical biomarkers are increasingly used for clinical trial enrollment in the neurodegenerative dis-
eases, suggesting that molecular definition(s) of PD are already emerging. We review candidate biomarkers for PD-related
pathologies and highlight the need for further validation.
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James Parkinson provided the first clinical def-
inition of the “shaking palsy” that now bears his
name in 1817. A little less than 100 years later,
Frederick Lewy reported the inclusion bodies that
are still used today in the neuropathological diag-
nosis of Parkinson’s disease (PD) [1]. While both
the clinical and neuropathological definitions of PD
have been updated many times since, two aspects
stand out. First, our fundamental definition of PD is
over 100 years old. Second, what has been notably
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missing in these updates is integration of the vast
amounts of molecular data that now characterize
much of our understanding of many other areas of
medicine, including the neurodegenerative diseases.
Indeed, although both Mendelian genetic approaches
and genome-wide association studies have identified
40+ genetic loci that confer varying degrees of risk
for PD [2], genetic data have yet to influence how
we diagnose PD, how we prognosticate for patients,
or how we make treatment choices. Similarly, despite
large-scale efforts at the international scale to develop
biochemical biomarkers for PD, none of this infor-
mation has crossed over into the clinic. The lack of
molecular integration in our approach to PD comes
into focus when we consider other areas of medicine
where, for example, it would be unimaginable to
diagnose, prognosticate, or determine a therapeutic
plan for most types of cancer at this point without
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molecular guidance, or where biochemical tests
(e.g., troponin and lipid measurements) routinely
affect decision-making about the care of cardiology
patients. It should also be noted that revised clinical
criteria to the other major neurodegenerative disease,
Alzheimer’s disease (AD), include biomarker evi-
dence of amyloid- (A) and tangle pathology, as
well as neurodegeneration, (i.e., the core pathological
features of the disease [3]).
Here, we pose three related questions as we con-
sider the future of PD research and clinical care. First:
Do we currently use molecular data in any of our vari-
ous working definitions of PD? Second: What are the
likely benefits of incorporating molecular data into
our definitions of PD? Third: What are the likely bar-
riers to a molecular view of PD? While we do not have
complete answers to all of these questions and while
we need to acknowledge the paucity of clinically val-
idated molecular markers of PD, we believe that the
partial answers that are emerging suggest that, for
therapeutic development, clinical trial, and clinical
management purposes, we should begin the process
of updating our definitions of PD for the molecular
age in which we live.
DO WE CURRENTLY USE MOLECULAR
DATA IN ANY OF OUR VARIOUS
WORKING DEFINITIONS OF PD?
We believe the answer is, increasingly, yes. That
is, while clinical definitions of PD are still based on
symptomatology, confirmed by the “gold standard”
of neuronal -synuclein-containing Lewy bodies at
autopsy, our working definitions of PD for mechanis-
tic research purposes as well as clinical trial entry are
already molecular in many cases. In preclinical mod-
els, animals with mutations (or loss of function) in
PD-associated genes such as GBA or LRRK2 are stud-
ied, and conclusions drawn from these models are not
assumed to hold true for all of PD, but rather for the
molecularly-defined subsets of PD patients who carry
mutations in these specific genes. Beyond the preclin-
ical research realm, Phase I and II trials of LRRK2
or GBA-targeting agents are not enrolling all-comers
with PD, but rather those PD patients molecularly
defined by mutations in these targets. Even the ongo-
ing Phase III trial of inosine for urate elevation in
PD, which does not target a genetically-defined sub-
set of patients, does use biochemical measures of
urate from the blood in its entry criteria, as well as
for proof of target engagement [4]. Thus, many signs
point to the entry of molecular information—in the
form of genetic data and biochemical measures from
patient-derived biofluids—into research and clinical
trial criteria now. Moreover, they suggest that we
need to be thinking of how this data might enter the
PD clinic in the near future and building in some of
the tools (e.g., genetic counseling) needed for such a
transition.
WHAT ARE THE LIKELY BENEFITS OF
INCORPORATING MOLECULAR DATA
INTO OUR DEFINITIONS OF PD?
For the clinic, in the near term, the benefits of incor-
porating molecular data into our definitions of PD
are likely to revolve around the ability to offer exper-
imental therapeutics for the patients most likely to
respond. To put real-world numbers on this bene-
fit, at the University of Pennsylvania (Penn), where
one of us practices PD patient care, 23 carriers of
GBA mutations have been identified over >10 years
of research efforts with a robust research patient
cohort; of these, fewer than 10 are eligible at this
point for the GBA-targeted clinical trials that are cur-
rently enrolling. If molecular characterization were
to encompass the entire clinical PD population at this
site (>2000 patients), we estimate that >100 (and pos-
sibly >200) PD patients with GBA mutations would
be identified, offering these patients the possibility of
enrolling in a targeted clinical trial for their currently
incurable disease. Indeed, September 2018 saw the
launch of the Molecular Integration in Neurological
Diagnosis (MIND) Initiative at Penn to do exactly
this all-comers genetic characterization.
For the clinical research arena, the potential bene-
fit is in the form of more efficient trials. As we have
previously described [5, 6], within-PD heterogeneity
is significant, with approximately 1/3 of PD patients
in the international Parkinson’s Progression Mark-
ers Initiative research cohort (modeled on the type
of cohort most likely to be used in a neuroprotective
trial) showing no increase in their MDS-UPDRS-III
score over 2 years of follow-up, which is the aver-
age length of a neuroprotective trial, while another
1/3 of PD patients in the same cohort show an aver-
age increase of >30 points. To discern a “signal”
amidst the “noise” of this degree of within-disease
heterogeneity, trials have to be quite large and, as
a consequence, costly. Integration of molecular data
in the selection of PD clinical trial participants may
result in greater trial efficiency. Indeed, as mentioned
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in the preceding section, current clinical trials target-
ing GBA, LRRK2, or inosine already use molecular
information in their enrollment criteria. To compare
with AD, it has become clear that the incorporation
of molecular data when recruiting patients for trials
is crucial; around 30% of patients with clinical signs
of AD do not have AD pathology, as determined by
A PET or CSF biomarker results [7], which is also
supported by autopsy findings [8]. If unnoticed, such
“AD mimics” would introduce considerable noise in
a trial of disease-modifying drug candidates directed
against A.
For the preclinical research arena, we believe that
loose definitions may have led to unnecessary dissen-
sion and/or red herrings in the past. For example, a
model of neuronal toxicity based on rotenone treat-
ment is unlikely to be the same biologically as a model
based on brain injection of abnormal conformations
of alpha-synuclein or one based on transgenic expres-
sion of a mutant form of LRRK2. Yet all three
are considered PD models. Rather than focusing on
the “PD” here, one might try to match the mecha-
nisms being studied to the specific PD patients in
which we have evidence of dysfunction in this exact
mechanism.
WHAT ARE THE LIKELY BARRIERS
TO A MOLECULAR VIEW OF PD?
The most likely barrier to embracing a molecular
view of PD follows directly from the points made
previously: we may end up concluding that PD is
not one disease, but many, and this will be diffi-
cult to accept. To some extent, fragmentation of the
relatively monolithic view of what constitutes PD is
already happening. As mentioned previously, trials of
GBA substrate reduction are not enrolling PD patients
who lack GBA mutations for the simple reason that
PD patients who have GBA mutations are most likely
to benefit from targeting this pathway. Other glimpses
of this fragmentation are also apparent to the careful
observer: the division between tremor-predominant
PD and non-tremor-predominant PD can be found
as early as Gowers’ statement in the 1880 s that
“In the majority of cases (two-thirds) the tremor
precedes the weakness; occasionally this relation is
reversed,” which is remarkably similar to the ratio
found by Jankovic in 800 patients (441:233) from
the DATATOP cohort in 1990 [9]. What was lack-
ing was a molecular “tag” for these subtypes, leading
to debate in the literature of the significance of
the tremor-predominant subtype if individuals might
change their clinical presentation over time [10].
Indeed, this debate motivated our 2016 report that a
single nucleotide polymorphism (SNP) near SNCA
defines a subtype of PD characterized by clinical
tremor-predominance, decreased cerebellar SNCA
RNA expression, and slower motor progression [11].
Importantly, while the “tremor-predominant” clinical
state may be demonstrably transient, a SNP genotype
is not. Thus, while our report that the rs356182 SNCA
SNP characterizes a clinically important subtype of
PD may be disproved over time, the SNP status
of an individual patient, unlike his or her tremor-
predominant state, is not similarly debatable.
Another key barrier is the lack of well-validated
biomarkers for the PD-related pathologies that con-
stitute our current “definitions” of disease. CSF total
tau, phospho-tau and A42 (preferably in a ratio with
Fig. 1. Clinical definitions of Parkinson’s disease (represented here by the 1886 William Gowers illustration) are over 200 years old, while
the Lewy body that still forms the basis of our pathological definitions was first described over 100 years ago. We argue that a molecular
“update” to our disease definitions, based on characterization of DNA and proteins obtained from the biofluids of individual patients, is
needed.
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the less aggregation-prone A40 that may be used
to normalize for inter-individual differences in A
production and clearance) may be used to exclude
individuals with AD-related pathologies, although
this is certainly complicated by the co-occurrence
of AD-related pathologies in the vast majority of
PD patients at autopsy [12]. CSF or serum/plasma
neurofilament light concentrations may be used to
differentiate PD from atypical parkinsonian disor-
ders, as neurofilament light levels are less elevated
in PD [13]. However, when it comes to positive
identification of Lewy body pathology, CSF -
synuclein concentration is not specific; currently
available tests do not differentiate normal from patho-
logical (inclusion-specific or -enriched) forms of
-synuclein and show only minor changes in PD
[14]. Novel tests for oligomeric or phosphorylated
forms of -synuclein show promising results but
are far from validated [15, 16]. The most promising
fluid-based biomarker assay for Lewy body pathol-
ogy at present detects the amplified biochemical
signal of -synuclein seeds that may be Lewy body-
derived in the CSF from PD patients but not in
healthy controls [17, 18]. In regards to positron
emission tomography, intense research is ongoing
to identify Lewy body-specific ligands but there
is no available method yet. Our hope, however, is
that the genetic and biochemical characterization of
patient-derived materials, using both targeted and
unbiased approaches [19], will make it possible
to subgroup clinical PD patients regarding progno-
sis, risk of various co-morbidities, and extent and
intensity of pathological processes. We note, addi-
tionally, that while genetic markers such as GBA and
LRRK2 mutation status are most mature at this point,
biochemical biomarkers are important to develop
as well, since they may reflect both genetic and
environmental influences. Patient-derived molecular
signatures—reflecting both genetic and environmen-
tal influences—should be useful when developing
and evaluating novel drug candidates.
What might it mean to have many types of PD,
rather than our current conception of PD as one
disease affecting a million people worldwide? Cer-
tainly, growing pains are expected. Indeed, we don’t
yet know what to make of the fact that among
the 55 LRRK2 mutation carriers with neuropathol-
ogy reported to date, a substantial fraction appear
not to have the Lewy body pathology that defines
PD (reviewed in [20])! It does seem unsatisfac-
tory to then conclude that these individuals do not
have PD.
We suspect, however, that the potential benefits far
outweigh these growing pains. Indeed, we predict that
for PD, as for many forms of cancer over the previous
decades, molecular definition (see Fig. 1) could be
truly transformative.
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